Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of analysts recently commented on SCYX shares. ValuEngine cut SCYNEXIS from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Guggenheim assumed coverage on SCYNEXIS in a research note on Tuesday, October 24th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Tuesday, August 29th.

Shares of SCYNEXIS (NASDAQ SCYX) traded down $0.04 during mid-day trading on Friday, hitting $2.22. The stock had a trading volume of 265,300 shares, compared to its average volume of 332,901. SCYNEXIS has a twelve month low of $1.52 and a twelve month high of $3.82. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.30 and a quick ratio of 7.30.

A number of hedge funds have recently made changes to their positions in SCYX. Federated Investors Inc. PA boosted its position in SCYNEXIS by 23.5% during the 2nd quarter. Federated Investors Inc. PA now owns 4,208,400 shares of the company’s stock worth $7,533,000 after acquiring an additional 800,040 shares during the period. GSA Capital Partners LLP lifted its holdings in shares of SCYNEXIS by 33.7% during the second quarter. GSA Capital Partners LLP now owns 176,700 shares of the company’s stock valued at $316,000 after purchasing an additional 44,500 shares during the last quarter. Vanguard Group Inc. raised its position in SCYNEXIS by 6.0% during the second quarter. Vanguard Group Inc. now owns 868,394 shares of the company’s stock valued at $1,554,000 after buying an additional 48,978 shares during the period. DAFNA Capital Management LLC raised its position in SCYNEXIS by 32.7% during the second quarter. DAFNA Capital Management LLC now owns 506,900 shares of the company’s stock valued at $907,000 after buying an additional 125,000 shares during the period. Finally, National Asset Management Inc. acquired a new position in SCYNEXIS during the second quarter valued at $551,000. Institutional investors own 31.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at


SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Analyst Recommendations for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with's FREE daily email newsletter.